Vincerx Pharma Inc
NASDAQ:VINC
Vincerx Pharma Inc
NASDAQ:VINC
Price:
0.93 USD
4.59%
Market Closed
Updated:
May 3, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of VINC.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VINC
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
VINC Competitors Multiples
Vincerx Pharma Inc Competitors
Vincerx Pharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Vincerx Pharma Inc
NASDAQ:VINC
|
19.9m USD | 0 | -0.5 | -0.2 | -0.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
149.1B USD | 5.3 | 22.2 | 16.5 | 24.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.1B USD | 10.4 | 28.5 | 22.8 | 23.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
102.6B USD | 7.8 | 25.9 | 17.4 | 19.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.2 | 35.4 | 21.4 | 26.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.4B USD | 3 | 168.2 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
48B USD | 7 | -10.2 | -11 | -9.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.1B USD | 3.2 | 26.6 | 13.7 | 17.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
